Overview

Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy and cisplatin in treating patients who have advanced head and neck cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Radiation Therapy Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cisplatin
Criteria
DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the oral cavity,
oropharynx, hypopharynx, or larynx Stage III or IV No distant metastases

PATIENT CHARACTERISTICS: Age: Not specified Performance status: Zubrod 0-1 Life expectancy:
At least 6 months Hematopoietic: Absolute granulocyte count at least 2,000/mm3 Platelet
count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT or SGPT no
greater than 2 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL
Creatinine clearance at least 50 mL/min Calcium normal Cardiovascular: No symptomatic
coronary artery disease No angina No myocardial infarction within the past 6 months Other:
Not pregnant or nursing Fertile patients must use effective contraception No other
malignancy within the past 3 years except nonmelanomatous skin cancer

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the
head and neck Surgery: No initial surgery (except diagnostic biopsy of the primary site or
neck)